Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03823079
Other study ID # FDRT-009
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 1, 2019
Est. completion date February 1, 2020

Study information

Verified date January 2019
Source Fudan University
Contact Ji Zhu, MD
Phone +86-2164175590
Email leo.zhu@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia.


Description:

Most patients with recurrent CRC have undergone a six-month postoperative adjuvant chemotherapy with oxaliplatin plus fluorouracil. Although the main dose-limiting side effect of oxaliplatin is neurotoxicity, with the widespread use of this drug, there are more and more reports that oxaliplatin is discontinued because of thrombocytopenia, which increases the risk of bleeding, rate of blood transfusion needs and length of stay. On the other hand, patients undergoing pelvic radiotherapy may also experience significant bone marrow suppression because flat bones such as the tibia may be exposed to high doses radiation. Low platelet counts is an urgent problem to be solved in order to give adequate quantitative radiotherapy. This randomized controlled clinical phase II study was designed to compare the effect of rhTPO with rhIL-11 in improving thrombocytopenia in patients with recurrent colorectal cancer who underwent radiotherapy and with thrombocytopenia, thus providing more evidence in clinical practice.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date February 1, 2020
Est. primary completion date September 1, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- The primary tumor is colorectal cancer, histologically proved recurrence or metastasis disease, or pelvic relapse within 6 months after oxaliplatin-based adjuvant chemotherapy.

- Not suitable for re-use of oxaliplatin and fluorouracil.

- No medication history of irinotecan.

- Lesions evaluable, and has indications for radiotherapy.

- UGT1A1*28 gene phenotype is 6/6 or 6/7

- Karnofsky physical condition score = 70

- Baseline platelet counts are 25-75×10^9/L, other bone marrow reserve and liver and kidney function meet the requirements of radiotherapy

- Able to follow the program during the study period

- Sign the informed consent

Exclusion Criteria:

- Pregnant or breastfeeding women

- Those with other history of malignant disease in the past 5 years, except for cured skin cancer and cervical carcinoma in situ

- If there is an uncontrolled history of epilepsy, central nervous system disease or mental disorder, the investigator may determine that the clinical severity may hinder the signing of informed consent or affect the patient's oral medication compliance.

- Clinically severe (ie, active) heart disease, such as symptomatic coronary heart disease, New York Heart Association (NYHA) class II or more severe congestive heart failure or severe arrhythmia requiring medication intervention (see appendix 12), or a history of myocardial infarction in the last 12 months

- Organ transplantation requires immunosuppressive therapy

- Severe uncontrolled recurrent infections, or other serious uncontrolled concomitant diseases

- Subject blood routine and biochemical indicators do not meet the following criteria: hemoglobin = 90g / L; absolute neutrophil count (ANC) = 1.5 × 109 / L; Alanine transaminase (ALT), aspartate aminotransferase (AST) = 2.5 times the upper limit of normal; alkaline phosphatase (ALP) =2.5 times the normal upper limit; serum total bilirubin <1.5 times the normal upper limit; serum creatinine <1 times the normal upper limit; serum albumin = 30g / L

- Anyone who is allergic to any research medication

Study Design


Intervention

Drug:
rhTPO
rhTPO 300u/kg, subcutaneous injection, qd
irinotecan
80mg/m2 (UGT1A1*28 6/6) or 65mg/m2 (UGT1A1*28 6/7)
Raltitrexed
3mg/m2 q3w
Radiation:
radiotherapy
in the use of intensity-modulated radiotherapy (IMRT) technology, the dose is judged according to the tumor site and radiotherapy purpose.
Drug:
rhIL-11
rhIL-11 50ug/kg, subcutaneous injection, qd

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Outcome

Type Measure Description Time frame Safety issue
Primary the rate of recovery of platelet accounts From date of chemoradiation until the date of first documented recovery, assessed up to 6 months
Primary the duration after returning to normal From date of first documented recovery until the date of first documented decrease of platelet accounts, assessed up to 6 months
Secondary cycles of concurrent chemotherapy patients received during radiotherapy through chemoradiation, an average of 5 weeks
Secondary change of participant quality of life during treatment as assessed by EORTC-quality of life questionnaire-C30 at the beginning and the end of chemoradiation.
Secondary change of participant quality of life during treatment as assessed by EuroQol-5 dimensional (EQ-5D) questionnaire at the beginning and the end of chemoradiation.
Secondary the rate of pathological complete response. pathological complete response (pCR) was defined no viable cancer cell under the examination of surgical resection specimen. Surgery scheduled 6-8 weeks after the end of chemoradiation
See also
  Status Clinical Trial Phase
Completed NCT00545545 - Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma Phase 1/Phase 2
Not yet recruiting NCT05518032 - Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Phase 2
Active, not recruiting NCT02738606 - Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery Phase 2
Recruiting NCT01365169 - Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" N/A
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Recruiting NCT04017650 - Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Phase 1/Phase 2
Active, not recruiting NCT01638533 - Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase 1
Recruiting NCT06307548 - Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer Phase 1/Phase 2
Active, not recruiting NCT02873195 - Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Phase 2
Completed NCT03095781 - Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Phase 1
Not yet recruiting NCT05883683 - Molecular Study and Precision Medicine for Colorectal Cancer
Completed NCT02973672 - Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas Phase 1/Phase 2
Terminated NCT02650635 - TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Phase 1
Terminated NCT02508077 - FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT04616183 - LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT02713373 - Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Phase 1/Phase 2
Active, not recruiting NCT02188264 - Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02465060 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Phase 2
Completed NCT03087591 - APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery Phase 1
Completed NCT03403634 - Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Phase 2